Skip to main content
Advertisement

AI Bias Analysis

4 models · Takes ~15 seconds

MarketWatch

With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug

With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
ShareXFacebook

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

M

Source

MarketWatch

Read full article at MarketWatch

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement